Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 4/20 | 0.58 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.55 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.54 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14073011 | 0.92 | P2RX7 (0.52) | GAAALDH1A1TSHRMAPTSMYD3 | |
| SCHEMBL14072965 | 0.84 | GAA (0.63) | GAAALDH1A1TSHRMAPTSMYD3 | |
| SCHEMBL14073071 | 0.84 | PARP1 (0.50) | GAAALDH1A1TSHRMAPTSMYD3 | |
| SCHEMBL29195071 | 0.80 | ALDH1A1 (0.65) | GAAALDH1A1TSHRMAPTSMYD3 | |
| SCHEMBL14072985 | 0.79 | TSHR (0.85) | GAAALDH1A1TSHRMAPTSMYD3 | |
| SCHEMBL14073622 | 0.77 | POLB (0.59) | ALDH1A1MAPTP2RX7LMNAPOLB | |
| SCHEMBL532478 | 0.77 | USP30 (0.67) | GAAALDH1A1TSHRMAPTSMYD3 | |
| SCHEMBL14073372 | 0.77 | KMT2A (0.54) | ALDH1A1TSHRMAPTPOLBMAOA | |
| SCHEMBL531798 | 0.77 | TSHR (0.74) | GAAALDH1A1TSHRMAPTSMYD3 | |
| SCHEMBL19691114 | 0.76 | GAA (0.70) | GAAALDH1A1TSHRMAPTSMYD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221093-A1 | Metalloprotease inhibitors containing a heterocyclic moiety | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080221093-A1 | Metalloprotease inhibitors containing a heterocyclic moiety | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221093-A1 | Metalloprotease inhibitors containing a heterocyclic moiety | MMP12, MMP13, MMP25 | GAA 208/4885ALDH1A1 714/4885TSHR 4343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.